23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
17:47 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Negative CHMP opinion for Portal VTE candidate

EMA's CHMP recommended against approval of Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to prevent venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness with risk factors for VTE, including VTE-related death....
21:59 , Mar 23, 2018 |  BC Extra  |  Company News

CHMP rebuffs Portola's betrixaban, Radius' abaloparatide-SC

EMA's CHMP issued negative opinions on Friday for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from Radius Health Inc. (NASDAQ:RDUS). The committee recommended against approval of Dexxience to prevent venous thromboembolism (VTE) in...
20:18 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Portola expects CHMP to recommend andexanet alfa, but not betrixaban

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said EMA's CHMP communicated a "positive trend vote" for an MAA for AndexXa andexanet alfa (IndexXa, PRT4445, PRT064445) to reverse the anticoagulant effects of Factor Xa inhibitors. However, Portola said the...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
16:21 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

CHMP requests more information on betrixaban VTE MAA

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said EMA’s CHMP requested additional information related to its MAA for betrixaban (PRT054021) for extended-duration prophylaxis of venous thromboembolism (VTE) in adults with acute medical illness and risk factors for VTE. Portola...
23:40 , Jul 7, 2017 |  BioCentury  |  Finance

Onward and upward

The top three market cap tiers continued to outperform smaller caps in 2Q17, led by companies valued between $1 billion and $9.9 billion. Companies valued below $1 billion failed to carry over their momentum from...
19:46 , Jul 5, 2017 |  BC Week In Review  |  Clinical News

FDA approves Portola's Bevyxxa betrixaban to prevent VTE

FDA approved an NDA from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) for Bevyxxa betrixaban (PRT054021) to prevent venous thromboembolism (VTE) in hospitalized and post-discharge adults with acute illnesses who are at high risk for complications. The oral...
19:14 , Jun 23, 2017 |  BC Extra  |  Company News

Portola soars after FDA approves anticoagulant Bevyxxa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) jumped $17.81 (47%) to $56.06 on Friday after FDA approved Bevyxxa betrixaban to prevent venous thromboembolism (VTE) in hospitalized and post-discharge adults with acute illnesses who are at high risk for...
22:45 , Apr 7, 2017 |  BioCentury  |  Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...